- Home
- SXTC vs LEXX Comparison
SXTC vs LEXX Comparison
Compare SXTC & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- LEXX
- Stock Information
- Founded
- SXTC 2005
- LEXX 2004
- Country
- SXTC China
- LEXX Canada
- Employees
- SXTC N/A
- LEXX N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- LEXX Health Care
- Exchange
- SXTC Nasdaq
- LEXX Nasdaq
- Market Cap
- SXTC 25.5M
- LEXX 20.9M
- IPO Year
- SXTC 2019
- LEXX N/A
- Fundamental
- Price
- SXTC $1.32
- LEXX $0.98
- Analyst Decision
- SXTC
- LEXX Strong Buy
- Analyst Count
- SXTC 0
- LEXX 1
- Target Price
- SXTC N/A
- LEXX $7.00
- AVG Volume (30 Days)
- SXTC 2.4M
- LEXX 90.9K
- Earning Date
- SXTC 01-01-0001
- LEXX 07-11-2025
- Dividend Yield
- SXTC N/A
- LEXX N/A
- EPS Growth
- SXTC N/A
- LEXX N/A
- EPS
- SXTC 20.77
- LEXX N/A
- Revenue
- SXTC $1,818,404.00
- LEXX $525,923.00
- Revenue This Year
- SXTC N/A
- LEXX $0.62
- Revenue Next Year
- SXTC N/A
- LEXX $14.19
- P/E Ratio
- SXTC $0.07
- LEXX N/A
- Revenue Growth
- SXTC 6.78
- LEXX 29.95
- 52 Week Low
- SXTC $0.95
- LEXX $0.95
- 52 Week High
- SXTC $11.92
- LEXX $4.44
- Technical
- Relative Strength Index (RSI)
- SXTC 41.43
- LEXX 37.32
- Support Level
- SXTC $1.34
- LEXX $1.00
- Resistance Level
- SXTC $1.76
- LEXX $1.05
- Average True Range (ATR)
- SXTC 0.23
- LEXX 0.06
- MACD
- SXTC -0.01
- LEXX 0.01
- Stochastic Oscillator
- SXTC 15.71
- LEXX 18.34
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.